Combination chemotherapy for metastatic breast cancer: Reaching for the cure

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 580-582

  Overmoyer, Beth ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; FEMALE; METASTASIS; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS;

EID: 0037441965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.085     Document Type: Editorial

References (24)

1. Fossati R, Confalonieri C, Torri V, et al: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460, 1998
2. Ahmann DL, Schaid DJ, Bisel HF, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 5:1928-1932, 1987
3. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
4. Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 16:3720-3730, 1998
5. Smalley RV, Murphy S, Huguley CM, et al: Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36:3911-3916, 1976
6. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979
7. Falkson G, Gelman RS, Leone L, et al: Survival of premenopausal women with metastatic breast cancer: Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 66:1621-1629, 1990
8. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998
9. Sawada N, Ishikawa T, Fukase Y, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019, 1998
10. Kurosumi M, Tabei T, Suemasu K, et al: Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7:945-948, 2000
11. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
12. Nabholtz JM, Mackey JR, Smylie M, et al: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19:314-321, 2001
13. Greenberg PAC, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996
14. Mackey JR, Paterson A, Dirix LY, et al: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35a, 2002 (abstr 137)
15. Nabholtz JM, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: Interim analysis of BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
16. National Institutes of Health Consensus Developmental Panel: National Institutes of Health consensus development conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
17. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
18. Sliwkowski MX, Lofgren JA, Lewis GD, et al: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70, 1999 (suppl)
19. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
20. Pegram MD, Slamon DJ: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 26:89-95, 1999 (suppl)
21. Pegram MD, Hsu S, Lewis G, et al: Inhibitory effects of combination of HER2 antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
22. Pegram M, Finn RS, Arzoo K, et al: The effect of HER2 overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
23. Pienkowski T, Fumoleau P, Eiermann W, et al: Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients: A phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 20:70b, 2001 (abstr 2030)
24. Slamon DJ, Patel R, Northfelt R, et al: Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2neu proto-oncogene: A pilot study of the UCLA Network. Proc Am Soc Clin Oncol 20:49a, 2001 (abstr 193)